CoChat

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

Johnston, Stephen R. D. · 2015 · Journal of the National Cancer Institute

The DOI matches its Crossref record; its reference list is not available.

Abstract

Overcoming primary or secondary endocrine resistance in breast cancer remains critical to further enhancing the benefit of existing therapies such as tamoxifen or an aromatase inhibitor (AI). Much progress has been made in understanding the molecular biology associated with secondary endocrine resistance. Cotargeting the estrogen receptor, together with various key intracellular proliferation and cell survival signaling pathways, has been explored as a strategy either to treat endocrine resistance once it develops in the second-line setting or to enhance first-line endocrine responsiveness by preventing secondary resistance from developing via blockade of specific pathways from the outset. While attempts to improve endocrine therapy by adding growth factor inhibitors have been disappointing, success resulting in new drug approvals has been seen in secondary endocrine resistance by treating patients with the mTOR antagonist everolimus in combination with the AI exemestane and, more recently, in the first-line setting, by the addition of the CDK 4/6 inhibitor palbociclib to the AI letrozole. Numerous other therapeutics are being evaluated in combination with endocrine therapies based on supportive preclinical evidence, including inhibitors of PI3K, Akt, HDAC, Src, IGFR-1, and FGFR. Appropriate clinical trial design and patient selection based on prior therapy exposure, together with predictive biomarkers derived through real-time molecular profiling, are needed to enrich future…

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/djv212

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 62 · Cited by 92

Research works printed but not linked: 1

  1. Hortobagyi, 2013, Genetic alterations and everolimus efficacy in hormone receptor–positive, HER-2–negative advanced breast cancer: preliminary correlative results from BOLERO-2 [oral], J Clin Oncol, 31

Metadata

Authors
Johnston, S. R. D.
Affiliations
Royal Marsden NHS Foundation Trust (GB)
Corresponding author
Johnston, Stephen R. D.
Venue
Journal of the National Cancer Institute
Published
2015-08-06
Volume
107
Issue
10
Pages
djv212
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W1994673501
Cited by
92
References
62
Citations by year
2026: 4 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 8 · 2020: 5 · 2019: 10 · 2018: 10 · 2017: 15 · 2016: 23 · 2015: 3
FWCI
3.03
Type
journal article
Language
en
Open access
closed
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
endocrine therapy, hormone receptor-positive breast cancer, advanced breast cancer, estrogen receptor, mTOR inhibition, everolimus, exemestane, palbociclib, letrozole, CDK4/6 inhibitors, aromatase inhibitors, PI3K/AKT inhibitors, histone deacetylase inhibitors, Src kinase inhibitor, FGFR inhibitors, predictive biomarkers, molecular profiling, clinical trial design
MeSH terms
Everolimus, Letrozole, Adult, Aged, Androstadienes, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Survival, Female, Humans, Middle Aged, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Research Design, Triazoles, Signal Transduction, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Aromatase Inhibitors, Protein Kinase Inhibitors, Cell Proliferation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. https://app.cochat.ai/papers/10.1093/jnci/djv212
The paper
Johnston, S. R. D. (2015). Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djv212

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.